Stock PVTT.F PIVOTAL THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Pivotal Therapeutics Inc.

Equities

PVTT.F

CA72582E1043

Market Closed - OTC Markets
Other stock markets
 20:17:54 23/03/2023 GMT 		5-day change 1st Jan Change
0.0018 USD +179,900.00% Intraday chart for Pivotal Therapeutics Inc. -.--% -.--%
2016 Pivotal Therapeutics Inc. Announces Management Changes CI
2015 Ford Teams with Pivotal to Speed Development of Connected Car Experiences Capitalizing on New Ford Sync Connect CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Pivotal Therapeutics Inc. Announces Management Changes
CI
Ford Teams with Pivotal to Speed Development of Connected Car Experiences Capitalizing on New Ford Sync Connect
CI
Pivotal Therapeutics Inc. Executes International Distribution Agreement with Healthcore Co. Ltd
CI
Pivotal Therapeutics Inc. Announces Earnings Results for the Nine Months Ended September 30, 2015
CI
Pivotal Therapeutics Inc. announced that it has received CAD 0.1 million in funding
CI
Pivotal Therapeutics Inc. announced that it expects to receive CAD 1.58 million in funding
CI
Pivotal Therapeutics Inc. Announces Financial Results for the Six Months Ended June 30, 2015
CI
Pivotal Therapeutics Inc. cancelled the transaction announced on June 29, 2015
CI
Pivotal Therapeutics Inc. announced that it expects to receive CAD 1.54 million in funding
CI
Pivotal Therapeutics Inc. Announces the Enrollment of the First Patient in Pivotal's POMEGA Phase IIa Clinical Trial with PVT-100
CI
Pivotal Therapeutics Inc. Announces Audited Consolidated Earnings Results for the Three Months Ended March 31, 2015
CI
Pivotal Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2014
CI
Pivotal Therapeutics Inc. Auditor Raises 'Going Concern' Doubt
CI
Pivotal Therapeutics Inc. Receives Health Canada Approval to Expand the Indication of Omazen
CI
Pivotal Therapeutics Inc. Executes Memorandum of Understanding for Distribution of Benefishial Line of Products in Korea
CI
Pivotal Therapeutics Inc. Receives Final Approval for Phase IIa Clinical Trial with PVT-100
CI
Pivotal Therapeutics Inc. Announces Earnings Results for the Three Months Ended September 30, 2014
CI
Pivotal Therapeutics Inc. Announces Resignation of Prakash Gowd as CFO
CI
Pivotal Therapeutics Inc. Announces Publication of Results of a Prospective Randomized Controlled Trial in the U.S
CI
Pivotal Therapeutics Inc. Announces Management Changes
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PVTT.F Stock
  4. News Pivotal Therapeutics Inc.